GBP14.13
1.62% yesterday
London, Jul 01, 05:36 pm CET
ISIN
GB00BN7SWP63
Symbol
GSK
Sector
Industry

GlaxoSmithKline Stock price

GBP14.13
-1.05 6.89% 1M
+0.97 7.35% 6M
+0.97 7.35% YTD
-0.48 3.32% 1Y
-1.83 11.47% 3Y
+0.95 7.18% 5Y
+5.75 68.67% 10Y
+8.88 169.19% 20Y
London, Closing price Tue, Jul 01 2025
+0.23 1.62%
ISIN
GB00BN7SWP63
Symbol
GSK
Sector
Industry

Key metrics

Basic
Market capitalization
GBP56.2b
Enterprise Value
GBP70.2b
Net debt
GBP13.9b
Cash
GBP4.5b
Shares outstanding
4.1b
Valuation (TTM | estimate)
P/E
18.59 | 8.03
P/S
1.78 | 1.70
EV/Sales
2.23 | 2.12
EV/FCF
18.12
P/B
4.14
Dividends
DPS
GBP0.61
Yield 1Y | 5Y
4.39% | 5.19%
Growth 1Y | 5Y
9.42% | -5.47%
Payout 1Y | 3Y
98.39% | 33.60%
Increased
1 Year
Financials (TTM | estimate)
Revenue
GBP31.5b | GBP33.5b
EBITDA
GBP7.9b | GBP11.3b
EBIT
GBP7.9b
Net Income
GBP3.2b | GBP7.2b
Free Cash Flow
GBP3.9b
Growth (TTM | estimate)
Revenue
2.57% | 6.70%
EBITDA
0.53% | 37.38%
EBIT
0.61%
Net Income
-29.68% | 178.60%
Free Cash Flow
-26.84%
Margin (TTM | estimate)
Gross
72.01%
EBITDA
25.15% | 33.62%
EBIT
24.96%
Net
10.00% | 21.43%
Free Cash Flow
12.29%
Financial Health
Equity Ratio
22.99%
Return on Equity
18.84%
ROCE
19.73%
ROIC
18.14%
Debt/Equity
1.30
More
EPS
GBP0.76
FCF per Share
GBP0.93
Short interest
60.00%
Employees
68.63k
Rev per Employee
GBP460.00k
Show more

Is GlaxoSmithKline a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,951 stocks worldwide.

GlaxoSmithKline Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a GlaxoSmithKline forecast:

5x Buy
16%
16x Hold
52%
10x Sell
32%

Analyst Opinions

31 Analysts have issued a GlaxoSmithKline forecast:

Buy
16%
Hold
52%
Sell
32%

Financial data from GlaxoSmithKline

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31,529 31,529
3% 3%
100%
- Direct Costs 8,826 8,826
5% 5%
28%
22,703 22,703
2% 2%
72%
- Selling and Administrative Expenses 9,055 9,055
1% 1%
29%
- Research and Development Expense 6,041 6,041
3% 3%
19%
7,931 7,931
1% 1%
25%
- Depreciation and Amortization 62 62
9% 9%
0%
EBIT (Operating Income) EBIT 7,869 7,869
1% 1%
25%
Net Profit 3,153 3,153
30% 30%
10%

In millions GBP.

Don't miss a Thing! We will send you all news about GlaxoSmithKline directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlaxoSmithKline Stock News

AD HOC NEWS
5 months ago
Der Pharmakonzern GSK GB00BN7SWP63 hat durch einen unerwartet starken Schlussspurt 2024 besser abgeschnitten als gedacht.
AD HOC NEWS
5 months ago
Der Pharmakonzern GSK GB00BN7SWP63 hat durch einen unerwartet starken Schlussspurt 2024 besser abgeschnitten als gedacht.

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Head office United Kingdom
CEO Emma Walmsley
Employees 68,629
Founded 1999
Website www.gsk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today